At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TSLP Kurv Yield Premium Strategy Tesla TSLA ETF
Market Closed 12-12 16:00:00 EST
24.54
+0.62
+2.59%
盘后24.54
+0.000.00%
16:45 EST
High24.54Low23.73Vol10.69K
Open24.09D1 Closing23.92Amplitude3.39%
Mkt Cap22.82MTradable Cap22.82MTotal Shares930.00K
T/O258.52KT/O Rate1.15%Tradable Shares930.00K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
prnewswire  ·  12-01
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
Upstream Bio to Participate in Upcoming December Investor Conferences
GlobeNewswire  ·  11-25
Upstream Bio to Participate in Upcoming December Investor Conferences
Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
Dow Jones  ·  11-10
Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
CSTONE PHARMA-B (02616): ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Academic Debut
Stock News  ·  11-07
CSTONE PHARMA-B (02616): ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Academic Debut
Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress
GlobeNewswire  ·  11-05
Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress
HK Stock Movement | KEYMED BIO-B (02162) Rises Over 3% Against Market Trend as CM512 Phase I Trial for Atopic Dermatitis Meets All Endpoints
Stock News  ·  11-05
HK Stock Movement | KEYMED BIO-B (02162) Rises Over 3% Against Market Trend as CM512 Phase I Trial for Atopic Dermatitis Meets All Endpoints
Upstream Bio to Participate in Upcoming November Investor Conferences
GlobeNewswire  ·  10-31
Upstream Bio to Participate in Upcoming November Investor Conferences
Upstream Bio’s verekitug shows prevention of TSLP binding in respiratory disease
TIPRANKS  ·  09-30
Upstream Bio’s verekitug shows prevention of TSLP binding in respiratory disease
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress
GlobeNewswire  ·  09-30
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress
Sanofi SA (SNY.US) Initiates Phase II/III Clinical Trials for TSLP/IL-13 Dual Antibody in COPD Treatment
Stock News  ·  09-26
Sanofi SA (SNY.US) Initiates Phase II/III Clinical Trials for TSLP/IL-13 Dual Antibody in COPD Treatment
CSTONE PHARMA-B (02616) to Present CS2015 (OX40L/TSLP Bispecific Antibody) at ACAAI 2025
Stock News  ·  09-15
CSTONE PHARMA-B (02616) to Present CS2015 (OX40L/TSLP Bispecific Antibody) at ACAAI 2025
Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
GlobeNewswire  ·  09-09
Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
GlobeNewswire  ·  09-02
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
SINO BIOPHARM (01177) to Present Research Results on "TQC3721 (PDE3/4 Inhibitor)", "TQC2731 (TSLP Monoclonal Antibody)", and "TQC3403 (Umeclidinium Bromide Vilanterol Dry Powder Inhaler)" at ERS 2025
Stock News  ·  08-25
SINO BIOPHARM (01177) to Present Research Results on "TQC3721 (PDE3/4 Inhibitor)", "TQC2731 (TSLP Monoclonal Antibody)", and "TQC3403 (Umeclidinium Bromide Vilanterol Dry Powder Inhaler)" at ERS 2025
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
GlobeNewswire  ·  08-11
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
GlobeNewswire  ·  08-06
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
GlobeNewswire  ·  07-08
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Introduction

Company Name.
Kurv Yield Premium Strategy Tesla TSLA ETF
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
The fund is an actively managed exchange traded fund that seeks current income while maintaining the opportunity for exposure to the share price (i.e., the price returns) of the common stock of Tesla Inc. (“TSLA”); however the strategy limits potential investment gains related to share price appreciation. The fund seeks to employ its investment strategy as it relates to TSLA in all market, economic, or other conditions. The fund is non-diversified.
Issue price:
--